多发性硬化症儿童与对照者中的MOG和AQP4抗体
本研究通过前瞻性病例对照研究,在美国14个中心纳入493例儿童期起病多发性硬化症(POMS)患者和703名健康对照,采用活细胞法检测血清MOG-IgG和AQP4-IgG。所有受试者AQP4-IgG均为阴性;MOG-IgG在30例(6%)POMS患者中阳性,对照者零例阳性,其中25例(83%)最终诊断为MOG-IgG相关疾病(MOGAD),5例(17%)维持多发性硬化症诊断。
要点
- 所有493例POMS患者和703名健康对照的AQP4-IgG均为阴性。
- MOG-IgG在30/493例POMS患者(6%)中阳性,健康对照零例阳性。
- 30例MOG-IgG阳性患者中25例(83%)最终诊断为MOGAD,5例(17%)维持多发性硬化症诊断。
核心结论
- MOG-IgG和AQP4-IgG在健康对照中均未检出,证实其对儿童中枢神经系统脱髓鞘疾病具有高特异性。
- 既往诊断为POMS的患者中5%最终为MOGAD,且无一例AQP4-IgG阳性。
- 在疑似多发性硬化症患者中,与最终MOGAD诊断相关的临床特征包括初始ADEM表型、发病年龄较小和缺乏EBV暴露。
研究设计与样本
- 前瞻性病例对照研究,在美国14个中心纳入493例POMS患者和703名健康对照。
- 采用活细胞法检测血清AQP4-IgG和MOG-IgG。
主要发现
- AQP4-IgG在所有1196名参与者(493例POMS和703名健康对照)中均为阴性。
- MOG-IgG在30/493例POMS患者(6%)中阳性,在健康对照中零例阳性。
- 30例MOG-IgG阳性患者中25例(83%)为MOGAD,5例(17%)经病历复核维持多发性硬化症诊断。
- MOGAD组较MS组女性更常见(21/25 [84%] vs 301/468 [64%];p=0.044),发病年龄更小(平均8.2±4.2 vs 14.7±2.6岁;p<0.001)。
- MOGAD组较MS组初始视神经症状更常见(16/25 [64%] vs 129/391 [33%];p=0.002),初始ADEM更常见(8/25 [32%] vs 9/468 [2%];p<0.001),初始脊髓症状较少见(3/20 [15%] vs 194/381 [51%];p=0.002),血清EBV阳性较少见(11/25 [44%] vs 445/468 [95%];p<0.001),脑脊液寡克隆带较少见(5/25 [20%] vs 243/352 [69%];p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to determine the frequency of myelin oligodendrocyte glycoprotein (MOG)-IgG and aquaporin-4 (AQP4)-IgG among patients with pediatric-onset multiple sclerosis (POMS) and healthy controls, to determine whether seropositive cases fulfilled their respective diagnostic criteria, to compare characteristics and outcomes in children with POMS versus MOG-IgG-associated disease (MOGAD), and identify clinical features associated with final diagnosis. METHODS: Patients with POMS and healthy controls were enrolled at 14 US sites through a prospective case-control study on POMS risk factors. Serum AQP4-IgG and MOG-IgG were assessed using live cell-based assays. RESULTS: AQP4-IgG was negative among all 1,196 participants, 493 with POMS and 703 healthy controls. MOG-IgG was positive in 30 of 493 cases (6%) and zero controls. Twenty-five of 30 patients positive with MOG-IgG (83%) had MOGAD, whereas 5 of 30 (17%) maintained a diagnosis of multiple sclerosis (MS) on re-review of records. MOGAD cases were more commonly in female patients (21/25 [84%] vs 301/468 [64%]; p = 0.044), younger age (mean = 8.2 ± 4.2 vs 14.7 ± 2.6 years; p < 0.001), more commonly had initial optic nerve symptoms (16/25 [64%] vs 129/391 [33%]; p = 0.002), or acute disseminated encephalomyelitis (ADEM; 8/25 [32%] vs 9/468 [2%]; p < 0.001), and less commonly had initial spinal cord symptoms (3/20 [15%] vs 194/381 [51%]; p = 0.002), serum Epstein-Barr virus (EBV) positivity (11/25 [44%] vs 445/468 [95%]; p < 0.001), or cerebrospinal fluid oligoclonal bands (5/25 [20%] vs 243/352 [69%]; p < 0.001). INTERPRETATION: MOG-IgG and AQP4-IgG were not identified among healthy controls confirming their high specificity for pediatric central nervous system (CNS) demyelinating disease. Five percent of those with prior POMS diagnoses ultimately had MOGAD; and none had AQP4-IgG positivity. Clinical features associated with a final diagnosis of MOGAD in those with suspected MS included initial ADEM phenotype, younger age at disease onset, and lack of EBV exposure. ANN NEUROL 2023;93:271-284.
引用
- Gaudioso CM, Mar S, Casper TC, et al. MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls. Ann Neurol. 2022. PMID: 36088544. doi:10.1002/ana.26502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。